CL2023001230A1 - Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos - Google Patents

Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos

Info

Publication number
CL2023001230A1
CL2023001230A1 CL2023001230A CL2023001230A CL2023001230A1 CL 2023001230 A1 CL2023001230 A1 CL 2023001230A1 CL 2023001230 A CL2023001230 A CL 2023001230A CL 2023001230 A CL2023001230 A CL 2023001230A CL 2023001230 A1 CL2023001230 A1 CL 2023001230A1
Authority
CL
Chile
Prior art keywords
deoxycytidine kinase
kinase inhibitor
crystal forms
crystalline forms
dck
Prior art date
Application number
CL2023001230A
Other languages
English (en)
Spanish (es)
Inventor
Litzinger David
A Schultz Kenneth
Original Assignee
Trethera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trethera Corp filed Critical Trethera Corp
Publication of CL2023001230A1 publication Critical patent/CL2023001230A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2023001230A 2020-11-02 2023-04-27 Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos CL2023001230A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108803P 2020-11-02 2020-11-02
US202163190107P 2021-05-18 2021-05-18

Publications (1)

Publication Number Publication Date
CL2023001230A1 true CL2023001230A1 (es) 2023-11-17

Family

ID=81380719

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001230A CL2023001230A1 (es) 2020-11-02 2023-04-27 Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos

Country Status (11)

Country Link
US (3) US20220133735A1 (https=)
EP (1) EP4237421A4 (https=)
JP (1) JP2023548605A (https=)
KR (1) KR20230129384A (https=)
AU (1) AU2021368138A1 (https=)
CA (1) CA3196694A1 (https=)
CL (1) CL2023001230A1 (https=)
MX (1) MX2023005056A (https=)
PE (1) PE20231656A1 (https=)
TW (1) TW202233613A (https=)
WO (1) WO2022094409A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094409A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
JP2002502086A (ja) 1998-01-23 2002-01-22 アナリティカ オブ ブランフォード インコーポレーテッド 表面からの質量分光測定
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
AU2003217274A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US7528160B2 (en) 2003-01-06 2009-05-05 Eli Lilly And Company Fused heterocyclic derivatives as PPAR modulators
EP1937658A1 (en) 2005-10-06 2008-07-02 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
US8552174B2 (en) 2005-10-31 2013-10-08 Agilent Technologies, Inc. Solutions, methods, and processes for deprotection of polynucleotides
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
US8093245B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. 4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use
AU2008302703B2 (en) 2007-09-19 2013-11-07 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
US9688673B2 (en) * 2011-03-08 2017-06-27 The Regents Of The University Of California Deoxycytidine kinase binding compounds
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
EA036177B1 (ru) 2013-08-13 2020-10-09 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Ингибиторы дезоксицитидинкиназы
US20190000850A1 (en) 2015-02-09 2019-01-03 The Regents Of The University Of California Combination cancer therapy
WO2016130562A2 (en) 2015-02-09 2016-08-18 The Regents Of The University Of California Metabolic analysis of the nucleotide de novo and salvage pathways
US10570124B2 (en) * 2016-01-08 2020-02-25 The Regents Of The University Of California Deoxycytidine kinase binding compounds
CN117205209A (zh) 2016-05-25 2023-12-12 新加坡保健服务集团 含有阿托品的水性组合物
EA201992780A1 (ru) * 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2019165073A1 (en) * 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2022094409A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Also Published As

Publication number Publication date
PE20231656A1 (es) 2023-10-17
US11446307B2 (en) 2022-09-20
JP2023548605A (ja) 2023-11-17
EP4237421A1 (en) 2023-09-06
US20220135555A1 (en) 2022-05-05
US20250049808A1 (en) 2025-02-13
WO2022094409A1 (en) 2022-05-05
AU2021368138A1 (en) 2023-06-22
TW202233613A (zh) 2022-09-01
CA3196694A1 (en) 2022-05-05
KR20230129384A (ko) 2023-09-08
EP4237421A4 (en) 2024-11-06
MX2023005056A (es) 2023-07-24
US20220133735A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
DOP2021000222A (es) Moduladores de la vía integrada del estrés
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
CL2022000998A1 (es) Inhibidores de las cinasas raf
CO2019011708A2 (es) Compuestos inhibidores de ask1 y usos de los mismos
MX381890B (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos
AR111233A1 (es) Inhibidores de tyk2, usos y métodos para la producción de los mismos
DOP2009000181A (es) Compuestos inhibidores de mek composiciones farmaceuticas que lo comprende y usos del mismo para la fabricacion de un medicamento
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
CO2024013744A2 (es) Moduladores de nlrp3
MX2019012945A (es) Formas cristalinas de un compuesto inhibidor de jak.
CL2022001887A1 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
CO2024009144A2 (es) Inhibidores de cinasa met
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
CO2022014499A2 (es) Moduladores de nlrp3
CL2024001566A1 (es) Moduladores de la vía integrada del estrés
MX2021012749A (es) Inhibidor selectivo de la jak1 cinasa.
MX2021013010A (es) Composiciones y metodos para modular la actividad del complemento.
UY38051A (es) INHIBIDORES DE LA PI4KIIIß
CL2020001461A1 (es) Inhibidores de dopamina–b–hidroxilasa.
CL2023001230A1 (es) Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
MX2022008148A (es) Inhibidores de btk.